

Technology Appraisal Committee Meeting (Committee B)

Minutes: Confirmed

Date and Time: Thursday 9 July 2015

Venue: Prospero House
241 Borough High Street
London
SE1 1GA

Present:	1. Chair, Dr Amanda Adler 2. Vice Chair, Professor Ruairidh Milne 3. Dr Jeff Aronson 4. Professor John Cairns 5. Professor Imran Chaudhry 6. Dr Neil Iosson 7. Mrs Anne Joshua 8. Dr Sanjay Kinra 9. Dr Miriam McCarthy 10. Mr Chris O'Regan 11. Professor Stephen Palmer 12. Dr Sanjeev Patel 13. Dr John Pounsford 14. Dr Danielle Preedy 15. Mr Alun Roebuck 16. Dr Nicky Welton	Present for all notes Present for all notes
-----------------	--	---

In attendance:

Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Dr Elisabeth George	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Jeremy Powell	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Stuart Wood	Administrator, National Institute for Health and Care Excellence	Present for all notes
Dr Mary Hughes	Technical Analyst,	Present for all notes

	National Institute for Health and Care Excellence	
Eleanor Donegan	Technical Adviser, National Institute for Health and Clinical Excellence	Present for all notes
Ewen Cummins	Health Economist, Evidence Review Group – Aberdeen	Present for notes 1 to 16
Dr Craig Ramsay	HCA Programme Director and Senior Statistician, Evidence Review Group – Aberdeen	Present for notes 1 to 16

Non-public observers:

Rebecca Dittrich	NICE International	Present for all notes
Jeremy Rodrigues	NICE Fellow	Present for al notes

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of enzalutamide for treating metastatic hormone-relapsed prostate cancer not previously treated with cytotoxic chemotherapy
2. The Chair informed the Committee of the non-public observers at this meeting: Rebecca Dittrich and Jeremy Rodrigues
3. Apologies were received from Dr Ray Armstrong, Mr Mark Chapman, Professor Daniel Hochhauser, Professor Ken Stein and Dr Marta Soares.

Any other Business

4. None

Notes from the last meeting

5. The minutes from the 14 May and 11 June committee meeting were approved.

Appraisal of enzalutamide for treating metastatic hormone-relapsed prostate cancer not previously treated with chemotherapy

Part 1 – Open session

6. The Chair welcomed the invited evidence review group: Ewen Cummins and Dr Craig Ramsay to the meeting and they introduced themselves to the Committee.

7. The Chair welcomed company representatives from Astellas to the meeting.
8. The Chair asked all Committee members to declare any relevant interests
 - 8.1. Dr Amanda Adler, Dr Jeff Aronson, Professor John Cairns, Professor Imran Chaudhry, Dr Neil Iosson, Mrs Anne Joshua, Dr Sanjay Kinra, Dr Miriam McCarthy, Professor Ruairidh Milne, Christopher O'Regan, Professor Stephen Palmer, Dr Sanjeev Patel, Dr John Poundsford, Dr Danielle Preedy, Mr Alun Roebuck and Dr Nicky Welton all declared that they knew of no personal specific pecuniary interest, personal non-specific pecuniary interest, non-personal specific pecuniary interest, non-personal non-specific pecuniary interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of enzalutamide for treating metastatic hormone-relapsed prostate cancer not previously treated with cytotoxic chemotherapy.
9. The Chair asked all NICE Staff to declare any relevant interests.
 - 9.1. All declared that they knew of no personal specific pecuniary interest, personal non-specific pecuniary interest, non-personal specific pecuniary interest, non-personal non-specific pecuniary interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of enzalutamide for treating metastatic hormone-relapsed prostate cancer not previously treated with cytotoxic chemotherapy.
10. The Chair asked the ERG to declare their relevant interests.
 - 10.1. All declared that they knew of no personal specific pecuniary interest, personal non-specific pecuniary interest, non-personal specific pecuniary interest, non-personal non-specific pecuniary interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of enzalutamide for treating metastatic hormone-relapsed prostate cancer not previously treated with cytotoxic chemotherapy.
11. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
12. The Committee proceeded to discuss the clinical effectiveness and cost effectiveness of enzalutamide for treating metastatic hormone-relapsed prostate cancer not previously treated with cytotoxic chemotherapy on the basis of the evidence before them. The discussions included:
 - 12.1. The comments from consultation relating to the use of abiraterone in current clinical practice and whether abiraterone was a relevant comparator
 - 12.2. The additional information provided by the company relating to how it adjusted the overall survival estimates from PREVAIL for treatments not used in the NHS and the rationale for its approach to extrapolating data in the model

- 12.3. Whether the PPRS rebate was relevant to the cost effectiveness estimates and to its decision making
- 12.4. The modelling assumptions stated to be the most plausible in the appraisal consultation document, and whether any of the comments received from consultation had changed its views on these
- 12.5. The incremental cost effectiveness analysis enzalutamide

13. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
14. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.
15. The Chair then thanked the experts, company representatives and academic group for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

16. Discussion continued on confidential information. This information was supplied by the company.
17. The Committee continued to discuss the clinical and cost effectiveness of enzalutamide for treating metastatic hormone-relapsed prostate cancer not previously treated with cytotoxic chemotherapy
18. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

19. Wednesday 12 August, 10.00am to 5.00pm at Prospero House, 241 Borough High Street, London, SE1 1GA.